

## Investment Research

### Buy

Recommendation unchanged

**Share price: EUR 12.52**

closing price as of 08/04/2014

**Target price: EUR 19.00**

Target Price unchanged

Reuters/Bloomberg

EUUG.DE/EUC.GY

Daily avg. no. trad. sh. 12 mth	28,366
Daily avg. trad. vol. 12 mth (m)	51.05
Price high 12 mth (EUR)	17.84
Price low 12 mth (EUR)	12.52
Abs. perf. 1 mth	-12.8%
Abs. perf. 3 mth	-20.3%
Abs. perf. 12 mth	-18.6%

Market capitalisation (EURm)	90
Current N° of shares (m)	7
Free float	100%

Key financials (EUR)	12/13	12/14e	12/15e
Sales (m)	329	344	365
EBITDA (m)	14	21	29
EBITDA margin	4.4%	6.1%	8.0%
EBIT (m)	6	12	20
EBIT margin	1.7%	3.5%	5.5%
Net Profit (adj.)(m)	3	7	12
ROCE	-2.7%	4.8%	6.5%
Net debt/(cash) (m)	66	69	65
Net Debt Equity	0.5	0.5	0.5
Net Debt/EBITDA	4.6	3.3	2.2
Int. cover(EBITDA/Fin.int)	3.8	5.1	8.2
EV/Sales	0.5	0.5	0.5
EV/EBITDA	12.5	8.2	5.7
EV/EBITDA (adj.)	9.1	7.5	5.7
EV/EBIT	32.7	14.2	8.2
P/E (adj.)	34.8	13.2	7.8
P/BV	0.8	0.7	0.7
OpFCF yield	12.7%	-2.7%	6.4%
Dividend yield	0.0%	1.6%	3.6%
EPS (adj.)	0.41	0.95	1.61
BVPS	17.03	17.79	19.19
DPS	0.00	0.20	0.45



Source: Reuters/Bloomberg, Euromicron AG, ESN (Preliminary)

For company description please see summary table footnote

## Final reporting confirmed our view Keep 'Buy'/PT EUR 19

**The facts:** Euromicron (EUCA) released final figures on Monday, March 31. Deviations were relatively small in comparison to the figures published on March 13. FY13 Revenues stood at EUR 329.4m (preliminaries: EUR 330m) and the EBITDA at EUR 14.4m (EUR 14.5m). One-off items for the integration phase and reshaping of the organization were said to be EUR 5.5m (EUR 5.5-6.0m). EUCA also mentioned that the neg. earnings effect from project valuations came to EUR 4.9m

**Management continued to guide for an EBITDA margin of 6-8% in FY14e at a top line of EUR 340-360m.** We had the impression that the 'Agenda 500', i.e. EUR 500m annualized revenues as of FY15e is even more in the focus. In the longer run, EUCA strives to return to an 8-11% EBIT margin.

The order backlog was released at EUR 126.5m. This was up 1% yoy. Thus, the FY13e book-to-bill ratio equals about 1x. **Management stated that the December level has been kept in the recent months and showed quite content with the current order situation.**

**Main take aways from the analyst conference:** 1/The company continues to focus a larger acquisition in 2015 to achieve the Agenda 500. The years thereafter should focus on the integration and might thus come with respective expenses again. In the meantime, EUCA screens the market for smaller targets. Unused credit lines at the end of FY13 were said to be EUR 71.7m according to the report.

2/FY14e should see further one-offs for integrations measure, but on a lower level compared to FY13.

3/EUCA might be able to recoup some portions of the amount mentioned above for project valuations. Clarity about this should be achieved in 1H14.

4/The company increased its factoring activities in FY14e to EUR 48m (up EUR 26m yoy). These activities distorted the cash level as EUCA has to transfer more than EUR 20m to its factoring partner. Consequently, **liquid assets (EUR 38.8m at year end) will decline to a normalized level.** 5/Taking further into account that purchase price liabilities amounting to EUR 9m were not yet paid, **the adjusted operating cash flow would have come to c. EUR 10m (3% of sales, but still up EUR 3m from the year before).** The reported figure stood at EUR 39.4m.

6/As the South segment continued to be loss making, **management decided not to build tax assets** in FY13e for the respective division. Hence, the tax line in FY13 came to minus 2.5m while EBT was at EUR 1.7m.

7/To highlight the restructuring effort, management showed that EUCA has still as many as 83 projects running, 39 of which for improving efficiency, 26 to increase revenues and 18 for cash-flow optimization. 47 projects are targeting the networks division, 14 the distribution and 22 are group-wide projects.

**Our analysis:** EUCA made clear that it continues to develop internal structures, projects and resources. Taking into account that most measures will be concluded in FY14e and the solid order situation, **there is a good chance that EUCA should deliver on the promised earnings improvements this year.** As can be seen overleaf, we have applied only major changes to our model. We continue to opt for the lower end of the EUCA outlook both as regards sales and earnings for the time being.

**Conclusion & Action:** Based on our largely unchanged model assumptions, we confirm both our 'Buy'/PT EUR 19 rating.

Analyst(s): Adrian Pehl, CFA

+49 69 58997 438 adrian.pehl@equinet-ag.de

## Model changes

EUR m	2014e old	2014e new	change	2015e old	2015e new	change	2016e old	2016e new	change
Group Sales	344.0	344.0	0%	365.0	365.0	0%	383.0	383.2	0%
Rep. group EBITDA	20.9	20.9	0%	29.4	29.1	-1%	32.6	32.1	-1%
EBITDA margin*	6.1%	6.1%	0bp	8.1%	8.0%	-10bp	8.5%	8.4%	-10bp
Rep. EPS [EUR]	0.75	0.76	1%	1.58	1.61	2%	1.89	1.93	2%

\*) here relative to sales and not total output

Sources: equinet estimates

## Discounted Cash Flow model

EUR m	Phase I					Phase II					Phase III
	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Sales	344.0	365.0	383.2	400.5	415.5	428.0	440.8	454.0	467.6	481.7	491.3
Sales growth	n/m	6.1%	5.0%	4.5%	3.8%	3.0%	3.0%	3.0%	3.0%	3.0%	2.0%
EBIT	12.0	20.2	23.1	25.5	27.4	25.1	26.0	27.0	27.9	28.8	29.6
EBIT margin	3.5%	5.5%	6.0%	6.4%	6.6%	5.9%	5.9%	5.9%	6.0%	6.0%	6.0%
Tax	(2.3)	(4.9)	(5.9)	(6.8)	(7.4)	(6.7)	(7.0)	(7.4)	(7.7)	(8.0)	(8.1)
Tax rate	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%	29.5%
NOPAT	9.7	15.3	17.2	18.8	20.0	18.3	19.0	19.6	20.2	20.8	21.5
Depreciation	8.9	8.9	9.0	9.2	9.5	9.5	9.6	9.7	9.9	10.0	10.1
in % of Sales	2.6%	2.4%	2.4%	2.3%	2.3%	2.2%	2.2%	2.1%	2.1%	2.1%	2.1%
Capex	(8.6)	(9.1)	(9.6)	(10.0)	(10.4)	(9.6)	(9.9)	(10.2)	(10.5)	(10.8)	(10.2)
in % of Sales	2.5%	2.5%	2.5%	2.5%	2.5%	2.3%	2.3%	2.3%	2.3%	2.3%	2.1%
Provision delta	0.3	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.2	0.2
in % of Sales	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.0%	0.0%	0.0%	0.0%
Change in working capita	(9.3)	(4.7)	(4.1)	(3.9)	(3.4)	(2.8)	(2.9)	(3.0)	(3.1)	(3.2)	(0.2)
in % of Sales	-2.7%	-1.3%	-1.1%	-1.0%	-0.8%	-0.7%	-0.7%	-0.7%	-0.7%	-0.7%	0.0%
Other current assets delt	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	(0.0)
in % of Sales	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Free Cash Flow	1.1	10.8	12.9	14.5	16.1	15.6	16.0	16.3	16.7	17.1	21.3
FCF growth	nm	nm	20.1%	22.2%	11.0%	-3.0%	2.5%	2.1%	2.3%	2.4%	24.2%
Present Value FCF	1.0	9.2	10.2	10.4	10.6	9.4	8.8	8.3	7.7	7.2	124.4

PV Phase I	41.4	MCap	106.2	Targ. equity ratio	83.9%			
PV Phase II	41.5	Risk premium	4.00%	Beta	1.34			
PV Phase III	124.4	Risk free rate	4.50%	WACC	9.23%			
Total present value	207.3							
+ capital increase/share buy back	0.0							
+ associates & other financial assets	0.9							
- market value of minorities	2.2							
+ cash and liquid assets	41.0							
- interest bearing debt**	110.5							
Implied Mcap	136.5							
Number of shares	7.2							
Implied value per share	19.03							
		Sensitivity		Growth rate Phase III				
		Analysis	1.0%	1.5%	2.0%	2.5%	3.0%	
			8.77%	18.77	19.93	21.26	22.80	24.60
			9.00%	17.82	18.89	20.10	21.51	23.15
		WACC	9.23%	16.92	17.90	19.03	20.31	21.81
			9.46%	16.07	16.98	18.02	19.20	20.56
			9.69%	15.27	16.12	17.07	18.16	19.41

\*) relative to sales and not total output; \*\*) including pension provisions

Source: equinet

**Euromicron AG: Summary tables**

<b>PROFIT &amp; LOSS (EURm)</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
<b>Sales</b>	<b>305</b>	<b>330</b>	<b>329</b>	<b>344</b>	<b>365</b>	<b>383</b>
Cost of Sales & Operating Costs	-275	-301	-309	-321	-336	-351
Non Recurrent Expenses/Income	0.0	-4.5	-5.5	-2.0	0.0	0.0
<b>EBITDA</b>	<b>30.8</b>	<b>25.0</b>	<b>14.4</b>	<b>20.9</b>	<b>29.1</b>	<b>32.1</b>
<b>EBITDA (adj.)*</b>	<b>30.8</b>	<b>29.5</b>	<b>19.9</b>	<b>22.9</b>	<b>29.1</b>	<b>32.1</b>
Depreciation	-2.9	-3.2	-3.5	-3.7	-3.9	-4.0
<b>EBITA</b>	<b>27.9</b>	<b>21.8</b>	<b>10.9</b>	<b>17.2</b>	<b>25.3</b>	<b>28.1</b>
<b>EBITA (adj.)*</b>	<b>27.9</b>	<b>26.3</b>	<b>16.4</b>	<b>19.2</b>	<b>25.3</b>	<b>28.1</b>
Amortisations and Write Downs of which PPA amortisation	0.0 -1.7	0.0 -2.0	0.0 -2.0	0.0 -1.5	0.0 -1.2	0.0 -1.2
<b>EBIT</b>	<b>24.2</b>	<b>17.1</b>	<b>5.5</b>	<b>12.0</b>	<b>20.2</b>	<b>23.1</b>
<b>EBIT (adj.)*</b>	<b>25.9</b>	<b>23.6</b>	<b>13.0</b>	<b>15.5</b>	<b>21.4</b>	<b>24.3</b>
Net Financial Interest	-5.3	-4.3	-3.8	-4.1	-3.6	-3.0
Other Financials	-1.0	-0.5	0.0	0.0	0.0	0.0
Associates	0.0	0.0	0.0	0.0	0.0	0.0
Other Non Recurrent Items	0.0	0.0	0.0	0.0	0.0	0.0
<b>Earnings Before Tax (EBT)</b>	<b>17.9</b>	<b>12.2</b>	<b>1.7</b>	<b>7.9</b>	<b>16.7</b>	<b>20.0</b>
Tax	-5.0	-3.4	-2.5	-2.3	-4.9	-5.9
<i>Tax rate</i>	<i>27.7%</i>	<i>27.8%</i>	<i>n.m.</i>	<i>29.5%</i>	<i>29.5%</i>	<i>29.5%</i>
Discontinued Operations	0.0	0.0	0.0	0.0	0.0	0.0
Minorities	-0.7	-0.3	-0.1	-0.2	-0.2	-0.3
<b>Net Profit (reported)</b>	<b>12.2</b>	<b>8.6</b>	<b>-0.9</b>	<b>5.4</b>	<b>11.5</b>	<b>13.9</b>
<b>Net Profit (adj.)</b>	<b>12.2</b>	<b>11.7</b>	<b>3.0</b>	<b>6.8</b>	<b>11.5</b>	<b>13.9</b>
<b>CASH FLOW (EURm)</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Cash Flow from Operations before change in NWC	21.7	18.1	9.8	15.5	19.6	23.9
Change in Net Working Capital	-28.3	-1.1	9.7	-9.3	-4.7	-4.1
<b>Cash Flow from Operations</b>	<b>-6.7</b>	<b>17.0</b>	<b>19.5</b>	<b>6.2</b>	<b>14.8</b>	<b>19.8</b>
Capex	-8.2	-10.8	-6.4	-8.6	-9.1	-9.6
Net Financial Investments	-27.7	-3.2	-10.6	0.0	0.0	0.0
<b>Free Cash Flow</b>	<b>-42.6</b>	<b>3.0</b>	<b>2.5</b>	<b>-2.4</b>	<b>5.7</b>	<b>10.2</b>
Dividends	-5.3	-6.0	-2.0	0.0	-1.4	-3.2
Other (incl. Capital Increase & share buy backs)	38.7	-15.0	10.9	-0.2	-0.2	-0.1
<b>Change in Net Debt</b>	<b>-9.2</b>	<b>-18.0</b>	<b>11.5</b>	<b>-2.6</b>	<b>4.1</b>	<b>6.8</b>
NOPLAT	18.7	17.0	-5.8	10.9	15.1	17.1
<b>BALANCE SHEET &amp; OTHER ITEMS (EURm)</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Net Tangible Assets	15.1	16.3	14.5	15.1	15.8	16.5
Net Intangible Assets (incl. Goodwill)	122	127	137	136	136	136
Net Financial Assets & Other	0.9	0.9	1.1	1.1	1.1	1.1
<b>Total Fixed Assets</b>	<b>138</b>	<b>145</b>	<b>153</b>	<b>153</b>	<b>153</b>	<b>153</b>
Inventories	25.1	27.5	28.0	29.2	31.0	32.6
Trade receivables	88.1	96.8	98.4	103	109	115
Other current assets	5.6	9.4	8.7	9.1	9.5	9.9
Cash (-)	-8.5	-5.6	-41.0	-17.1	-16.9	-9.2
<b>Total Current Assets</b>	<b>127</b>	<b>139</b>	<b>176</b>	<b>159</b>	<b>167</b>	<b>167</b>
<b>Total Assets</b>	<b>266</b>	<b>284</b>	<b>329</b>	<b>311</b>	<b>320</b>	<b>320</b>
Shareholders Equity	120	119	122	128	138	148
Minority	0.5	0.5	0.4	0.6	0.8	1.1
Total Equity	120	119	123	128	139	149
Long term interest bearing debt	35.5	45.6	40.1	18.8	14.5	0.0
Provisions	10.4	11.9	13.7	14.9	14.0	15.0
Other long term liabilities	1.5	6.2	4.6	4.6	4.6	4.6
<b>Total Long Term Liabilities</b>	<b>47.3</b>	<b>63.8</b>	<b>58.4</b>	<b>38.3</b>	<b>33.0</b>	<b>19.5</b>
Short term interest bearing debt	32.7	37.8	67.2	67.2	67.2	67.2
Trade payables	31.6	42.9	54.6	51.6	54.7	57.5
Other current liabilities	33.9	20.4	26.0	25.9	26.1	26.3
<b>Total Current Liabilities</b>	<b>98.3</b>	<b>101</b>	<b>148</b>	<b>145</b>	<b>148</b>	<b>151</b>
<b>Total Liabilities and Shareholders' Equity</b>	<b>266</b>	<b>284</b>	<b>329</b>	<b>311</b>	<b>320</b>	<b>320</b>
<b>Net Capital Employed</b>	<b>192</b>	<b>215</b>	<b>207</b>	<b>217</b>	<b>222</b>	<b>227</b>
<b>Net Working Capital</b>	<b>76.8</b>	<b>77.9</b>	<b>68.2</b>	<b>77.4</b>	<b>82.1</b>	<b>86.2</b>
<b>GROWTH &amp; MARGINS</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
<i>Sales growth</i>	<i>49.9%</i>	<i>8.1%</i>	<i>-0.2%</i>	<i>4.4%</i>	<i>6.1%</i>	<i>5.0%</i>
<b>EBITDA (adj.)* growth</b>	<b>24.5%</b>	<b>-4.1%</b>	<b>-32.6%</b>	<b>14.8%</b>	<b>27.5%</b>	<b>10.3%</b>
<i>EBITA (adj.)* growth</i>	<i>23.6%</i>	<i>-5.6%</i>	<i>-37.8%</i>	<i>17.1%</i>	<i>31.9%</i>	<i>11.1%</i>
<i>EBIT (adj.)* growth</i>	<i>28.8%</i>	<i>-9.0%</i>	<i>-44.8%</i>	<i>19.2%</i>	<i>38.2%</i>	<i>13.3%</i>



## Euromicron AG: Summary tables

<b>GROWTH &amp; MARGINS</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Net Profit growth	6.7%	-4.2%	-74.7%	130.6%	68.9%	20.2%
EPS adj. growth	-2.0%	-24.5%	-76.5%	130.6%	68.9%	20.2%
DPS adj. growth	4.5%	-73.9%	n.m.	n.m.	125.0%	22.2%
EBITDA (adj)* margin	10.1%	8.9%	6.0%	6.6%	8.0%	8.4%
EBITA (adj)* margin	9.1%	8.0%	5.0%	5.6%	6.9%	7.3%
EBIT (adj)* margin	8.5%	7.1%	3.9%	4.5%	5.9%	6.3%
<b>RATIOS</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Net Debt/Equity	0.5	0.7	0.5	0.5	0.5	0.4
Net Debt/EBITDA	1.9	3.1	4.6	3.3	2.2	1.8
Interest cover (EBITDA/Fin.interest)	5.8	5.8	3.8	5.1	8.2	10.6
Capex/D&A	125.6%	136.4%	71.7%	97.1%	102.4%	105.9%
Capex/Sales	2.7%	3.3%	1.9%	2.5%	2.5%	2.5%
NWC/Sales	25.2%	23.6%	20.7%	22.5%	22.5%	22.5%
ROE (average)	11.7%	9.8%	2.5%	5.5%	8.7%	9.7%
ROCE (adj.)	8.7%	7.7%	-2.7%	4.8%	6.5%	7.2%
WACC	9.2%	9.2%	9.2%	9.2%	9.2%	9.2%
ROCE (adj.)/WACC	0.9	0.8	-0.3	0.5	0.7	0.8
<b>PER SHARE DATA (EUR)***</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Average diluted number of shares	5.2	6.7	7.2	7.2	7.2	7.2
EPS (reported)	2.33	1.29	-0.12	0.76	1.61	1.93
EPS (adj.)	2.33	1.76	0.41	0.95	1.61	1.93
BVPS	22.81	17.79	17.03	17.79	19.19	20.67
DPS	1.15	0.30	0.00	0.20	0.45	0.55
<b>VALUATION</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
EV/Sales	0.5	0.6	0.5	0.5	0.5	0.4
EV/EBITDA	5.2	8.4	12.5	8.2	5.7	5.0
<b>EV/EBITDA (adj.)*</b>	<b>5.2</b>	<b>7.2</b>	<b>9.1</b>	<b>7.5</b>	<b>5.7</b>	<b>5.0</b>
EV/EBITA	5.7	9.7	16.6	9.9	6.6	5.7
<b>EV/EBITA (adj.)*</b>	<b>5.7</b>	<b>8.0</b>	<b>11.0</b>	<b>8.9</b>	<b>6.6</b>	<b>5.7</b>
EV/EBIT	6.6	12.4	32.7	14.2	8.2	7.0
<b>EV/EBIT (adj.)*</b>	<b>6.2</b>	<b>9.0</b>	<b>13.9</b>	<b>11.0</b>	<b>7.8</b>	<b>6.6</b>
<b>P/E (adj.)</b>	<b>6.8</b>	<b>10.3</b>	<b>34.8</b>	<b>13.2</b>	<b>7.8</b>	<b>6.5</b>
P/BV	0.7	1.0	0.8	0.7	0.7	0.6
Total Yield Ratio	7.2%	1.7%	0.0%	1.6%	3.6%	4.4%
EV/CE	0.7	1.0	0.8	0.7	0.7	0.7
OpFCF yield	-17.8%	5.1%	12.7%	-2.7%	6.4%	11.4%
OpFCF/EV	-9.3%	2.9%	7.3%	-1.4%	3.4%	6.4%
Payout ratio	49.4%	23.3%	0.0%	26.4%	28.0%	28.5%
Dividend yield (gross)	7.2%	1.7%	0.0%	1.6%	3.6%	4.4%
<b>EV AND MKT CAP (EURm)</b>	<b>12/2011</b>	<b>12/2012</b>	<b>12/2013</b>	<b>12/2014e</b>	<b>12/2015e</b>	<b>12/2016e</b>
Price** (EUR)	15.93	18.14	14.35	12.52	12.52	12.52
Outstanding number of shares for main stock	5.2	6.7	7.2	7.2	7.2	7.2
<b>Total Market Cap</b>	<b>84</b>	<b>121</b>	<b>103</b>	<b>90</b>	<b>90</b>	<b>90</b>
<b>Net Debt</b>	<b>60</b>	<b>78</b>	<b>66</b>	<b>69</b>	<b>65</b>	<b>58</b>
<i>o/w Cash &amp; Marketable Securities (-)</i>	<i>-8</i>	<i>-6</i>	<i>-41</i>	<i>-17</i>	<i>-17</i>	<i>-9</i>
<i>o/w Gross Debt (+)</i>	<i>68</i>	<i>83</i>	<i>107</i>	<i>86</i>	<i>82</i>	<i>67</i>
<b>Other EV components</b>	<b>17</b>	<b>13</b>	<b>11</b>	<b>12</b>	<b>12</b>	<b>13</b>
<b>Enterprise Value (EV adj.)</b>	<b>160</b>	<b>211</b>	<b>180</b>	<b>170</b>	<b>167</b>	<b>161</b>

Source: Company, Equinet Bank estimates.

### Notes

\* Where EBITDA (adj.) or EBITA (adj.) = EBITDA (or EBITA) +/- Non Recurrent Expenses/Income and where EBIT (adj.) = EBIT +/- Non Recurrent Expenses/Income - PPA amortisation

\*\*Price (in local currency): Fiscal year end price for Historical Years and Current Price for current and forecasted years

Sector: Electronic & Electrical Equipment/Electrical Components & Equipment

Company Description: The euromicron Group with its extensive network of branch offices in Germany is a system house that is active in the future market of network and fiber optics technology. euromicron develops, produces and distributes network components based on copper, glass fiber and wireless technology and plans, implements and maintains communications, information and security networks for all applications.



## Recommendations and Disclosures

Coverage	Analyst	Target	Rating	Disc.	Coverage	Analyst	Target	Rating	Disc.
2GENERGY	Freudenreich	34.50	Buy	2/3/5	K+S AG	Schäfer	28.00	Buy	
4SC	Miemietz	3.60	Buy	7	Kontron	Pehl	5.60	Accumulate	
Aareal Bank	Häßler	33.00	Accumulate		KronesAG	Schmidt	76.00	Buy	
Adler Modemaerkte	Faust	12.70	Buy	3/5	KTGAgar	Schäfer	16.00	Accumulate	2/3/5
Adpepper	Lieder / Pehl	1.70	Buy	2/3	KUKA	Schmidt	34.00	Hold	
adidas	Faust	105.00	Buy		LANXESS	Demidova	54.00	Hold	
Advanced Vision Technology	Schmidt	7.00	Buy		Leoni	Schuldt	58.00	Accumulate	
AgrariusAG	Schäfer	1.25	Buy	2/3/5	Linde	Demidova	160.00	Accumulate	
Aixtron	Pehl	8.50	Sell	2/3	Loewe	Faust	Suspended	Suspended	2/5
Allianz	Häßler	130.00	Hold		Logwin	Rothenbacher	1.60	Buy	2/3/5
Analytik Jena	Demidova	14.00	Hold	7	Luft hansa	Rothenbacher	19.00	Hold	
BASF	Demidova	88.00	Accumulate		MAN	Schuldt	85.00	Hold	
BAUER AG	Schmidt	18.00	Hold		MAXAutomation AG	Schmidt	6.40	Buy	2/3
Bayer	Miemietz	96.00	Hold		Medion	Faust	13.00	Hold	
BayWa	Schäfer	45.00	Accumulate	5	Merck	Miemietz	133.00	Accumulate	
BB Biotech	Miemietz	149.00	Hold	7	Metro	Faust	43.00	Buy	
Beiersdorf	Demidova	64.00	Sell		MIFA	Faust	Suspended	Suspended	2/3/4/5
Berentzen	Faust	5.60	Hold	2/3	MLP	Häßler	6.30	Accumulate	2/3
BILFINGER SE	Faust	92.00	Accumulate		MTU	Pehl	68.50	Hold	2
Biotest	Miemietz	93.50	Hold	2/3/5	Munich Re	Häßler	150.00	Hold	
BMW	Schuldt	110.00	Buy		Nanogate AG	Demidova	38.00	Accumulate	2/3/5
Celesio	Lieder	23.50	Under Review		PATRIZIA AG	Häßler	9.10	Buy	
Cenit	Pehl	12.75	Buy	2/3	Pfeiffer Vacuum	Pehl	83.00	Reduce	
comdirect	Häßler	9.50	Accumulate		Phoenix Solar	Freudenreich	Suspended	Suspended	
Commerzbank	Häßler	13.00	Hold		Porsche	Schuldt	64.00	Hold	
Continental	Schuldt	158.00	Hold		Postbank	Häßler	32.00	Accumulate	
CYTOTOOLS AG	Miemietz	58.00	Accumulate	2/3	PSI	Schäfer	13.50	Hold	2/3
Daimler AG	Schuldt	59.00	Reduce		Puma	Faust	210.00	Hold	
Daldrup & Soehne	Schäfer	15.00	Accumulate	2/3/5	Rheinmetall	Pehl	55.00	Accumulate	
Deutsche Bank	Häßler	42.00	Buy		Rhoen-Klinikum	Lieder	25.00	Accumulate	
Deutsche Biogas	Schäfer	6.00	Buy	2/3/5	RIB Software	Rothenbacher	15.00	Buy	2/3
Deutsche Boerse	Häßler	50.00	Sell		RWE	Schäfer	25.00	Hold	
Deutsche EuroShop	Rothenbacher	33.00	Hold		SAF-HOLLAND	Schuldt	13.60	Buy	7
Deutsche Forfait	Häßler	5.60	Rating Suspended	2/3/4/5	Salzgitter	Freudenreich	34.00	Buy	
Deutsche Post	Rothenbacher	24.00	Reduce		Seven PrinciplesAG	Pehl	6.00	Buy	2/3/5
Deutsche Telekom	Pehl	13.00	Hold		SIEGFRIED HOLDINGAG	Miemietz	202.00	Buy	7
Deutz AG	Schmidt	8.00	Buy		Singulus Technologies	Freudenreich	2.30	Hold	4/5
DMGMORI SEIKI AG	Schmidt	30.00	Accumulate		SKWStahl	Freudenreich	23.00	Buy	
Douglas Holding	Faust	38.00	Hold		SMA Solar Technology	Freudenreich	26.00	Sell	
Draegerwerk	Lieder	87.00	Reduce		SMTSCHARFAG	Schmidt	25.00	Accumulate	2/3
Drillisch	Pehl	27.50	Accumulate		SolarWorld	Freudenreich	0.05	Sell	
E.ON	Schäfer	14.00	Hold		SuessMicroTec	Pehl	8.00	Hold	2/3
EringKlunger	Schuldt	20.00	Reduce		SURTECO	Lieder	26.00	Buy	2/3
EpigenomicsAG	Miemietz	8.00	Buy	2/3/5	Symrise AG	Demidova	36.00	Hold	
Euromicron AG	Pehl	19.00	Buy	2/3	SYZGYAG	Lieder / Pehl	6.10	Accumulate	2/3
Evonik	Demidova	34.00	Accumulate		Talanx Group	Häßler	28.00	Accumulate	
Fielmann	Lieder	89.00	Hold		ThyssenKrupp	Freudenreich	17.00	Sell	
Fraport	Rothenbacher	61.00	Accumulate		TUI	Rothenbacher	15.00	Accumulate	
Freenet	Pehl	25.00	Hold	2	United Internet	Pehl	34.00	Hold	
Fresenius	Lieder	117.00	Hold		Uzin Utz	Lieder	26.00	Buy	2/3
Fresenius Medical Care	Lieder	58.00	Buy		VBH Holding	Faust	2.80	Hold	2/3
FuchsPetrolub	Demidova	54.00	Reduce		VIB Vermoegen	Rothenbacher	14.00	Accumulate	
GEA Group	Schmidt	38.00	Accumulate		Volkswagen	Schuldt	250.00	Buy	
Gerrheimer AG	Lieder	45.00	Reduce		Vossloh	Schmidt	60.00	Reduce	
GERRYWEBER	Faust	40.00	Accumulate		Wacker Chemie	Freudenreich	71.00	Sell	
Gesco	Schmidt	78.00	Accumulate	2/3	Willex	Miemietz	1.50	Buy	2/3
GFT Technologies	Schuldt	9.40	Buy	2/3	Wincor Nixdorf	Pehl	61.00	Accumulate	2
Gigaset	Pehl	1.00	Hold	2/3/4/5					
GrenkeleasingAG	Häßler	70.00	Hold						
Hannover Re	Häßler	70.00	Buy						
Heidelberger Druck	Schmidt	3.00	Buy						
Henkel	Demidova	80.00	Hold						
HHLA	Rothenbacher	16.00	Reduce						
Hochtief	Faust	69.00	Hold						
Hugo Boss	Faust	88.00	Reduce						
i:FAOAG	Rothenbacher	19.00	Buy	2/3					
Joyou AG	Lieder	21.90	Buy	2					

Source: equinet Recommendations



## Notice according to § 34 b (German) Securities Trading Act (“Wertpapierhandelsgesetz”)

This document is issued by Equinet Bank AG (“Equinet Bank”). It has been prepared by its authors independently of the Company, and none of Equinet Bank, the Company or its shareholders has independently verified any of the information given in this document.

Equinet Bank possesses relations to the covered companies as detailed in the table on the previous page. Additional information and disclosures will be made available upon request and/or can be looked up on our website <http://www.Equinet Bank-ag.de>

- 1 - Equinet Bank and/or its affiliate(s) hold(s) more than 5% of the share capital of this company calculated under computational methods required by German law.
- 2 - Equinet Bank acts as a designated sponsor for this company, including the provision of bid and ask offers. Therefore, we regularly possess shares of the company in our proprietary trading books. Equinet Bank receives a commission from the company for the provision of the designated sponsor services.
- 3 – The designated sponsor services include a contractually agreed provision of research services.
- 4 – Within the last twelve months, Equinet Bank was involved as a lead or co-lead manager in the public offering of securities which are/whose issuer is the subject of this report.
- 5 – Within the last twelve months, Equinet Bank and/or its affiliate(s) provided investment banking- and/or other consultancy services for this company and/or it's shareholders.
- 6 - Equinet Bank and/or its affiliate(s) has/have other substantial financial interests in relation to this issuer.
- 7 – Equinet Bank has entered into an agreement with this company about the preparation of research reports and – in return - receives a compensation.

Companies of the Equinet Bank group and/or its directors, officers and employees or clients may take positions in, and may make purchases and/or sales as principal or agent in the securities or related financial instruments discussed in our reports. The Equinet Bank group may provide investment banking and other services to and/or serve as directors of the companies referred to in our reports.

In compliance with Para 5 Sec. 4 of the Ordinance on the Analysis of Financial Instruments (FinAnV) Equinet Bank has realized additional internal and organizational measures, such as specific research guidelines, to prevent or manage conflicts of interest.

Neither the company nor its employees are allowed to receive donations from third parties with a special interest in the content of the analysis.

The salary of the research analysts of Equinet Bank AG does not depend on the investment banking transactions of the company. Nevertheless, this does not rule out the payment of a bonus which depends on the overall financial performance of the bank.

Particular care is taken that the individual performance of each research analyst of Equinet Bank AG is not being assessed by a manager of another business division with similar or same interests.

To assure a highest degree of transparency Equinet Bank AG regularly provides - on a quarterly basis - a summary according to Para 5 Sec. 4 No. 3 of the Ordinance on the Analysis of Financial Instruments (FinAnV). It informs about the overall analysts recommendations and sets them in a relationship to those companies, for which Equinet Bank provided investment banking services within the last twelve months. This summary is published via our website <http://www.Equinet Bank-ag.de>.

Furthermore, we refer to our conflict of interest policy as well as the German Securities Trading Act (WpHG) and the Ordinance on the Analysis of Financial Instruments (FinAnV) provided in the download area of our website <http://www.Equinet Bank-ag.de>.

## Remarks

### Recommendation System

- Buy - The stock is expected to generate a total return of over 20% during the next 12 months time horizon.
- Accumulate - The stock is expected to generate a total return of 10% to 20% during the next 12 months time horizon.
- Hold - The stock is expected to generate a total return of 0% to 10% during the next 12 months time horizon
- Reduce - The stock is expected to generate a total return of 0 to -10% during the next 12 months time horizon
- Sell - The stock is expected to generate a total return below -10% during the next 12 months time horizon

### Basis of Valuation

Equinet Bank uses for valuation purposes primarily DCF-Valuations and Sum-Of-The-Parts-Valuations as well as peer group comparisons.

### Share prices

Share prices in this analysis are the German closing prices of the last trading day before the publication.

### Sources

Equinet Bank has made any effort to carefully research all information contained in the analysis. The information on which the analysis is based has been obtained from sources which we believe to be reliable such as, for example, Reuters, Bloomberg and the relevant press as well as the company which is the subject of the analysis. Only that part of the research note is made available to the issuer, who is the subject of the analysis, which is necessary to properly reconcile with the facts. Should this result in considerable changes a reference is made in the research note.

### Actualizations

Opinions expressed in this analysis are our current opinions as of the issuing date indicated on this document. We do not commit ourselves in advance to whether and in which intervals updates are made.



## DISCLAIMER

THE PREPARATION OF THIS DOCUMENT IS SUBJECT TO REGULATION BY GERMAN LAW. THIS DOCUMENT IS BEING SUPPLIED TO YOU SOLELY IN YOUR CAPACITY AS A PROFESSIONAL INSTITUTIONAL INVESTOR FOR YOUR INFORMATION AND MAY NOT BE REPRODUCED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. NEITHER THIS DOCUMENT NOR ANY COPY OF IT MAY BE TAKEN OR TRANSMITTED INTO AUSTRALIA, CANADA OR JAPAN OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA OR JAPAN OR TO ANY RESIDENT THEREOF.

THE DELIVERY OF THIS RESEARCH REPORT TO U.S. PERSONS IN THE UNITED STATES OF AMERICA IS MADE BY AND UNDER THE RESPONSIBILITY OF GSN NA, INC. (REGISTERED WITH THE SEC). THIS RESEARCH REPORT IS ONLY INTENDED FOR PERSONS WHO QUALIFY AS MAJOR U.S. INSTITUTIONAL INVESTORS, AS DEFINED IN SECURITIES EXCHANGE ACT RULE 15A-6, AND DEAL WITH GSN NA, INC. HOWEVER, THE DELIVERY OF THIS RESEARCH REPORT OR SUMMARY TO ANY U.S. PERSON SHALL NOT BE DEEMED A RECOMMENDATION OF GSN NA, INC. TO EFFECT ANY TRANSACTIONS IN THE SECURITIES DISCUSSED HEREIN OR AN ENDORSEMENT OF ANY OPINION EXPRESSED HEREIN. GSN NA, INC. MAY FURNISH UPON REQUEST ALL INVESTMENT INFORMATION AVAILABLE TO IT SUPPORTING ANY RECOMMENDATIONS MADE IN THIS RESEARCH REPORT. ALL TRADES WITH U.S. RECIPIENTS OF THIS RESEARCH SHALL BE EXECUTED THROUGH GSN NA, INC.

THIS DOCUMENT IS FOR DISTRIBUTION IN THE U.K. ONLY TO PERSONS WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS AND FALL WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR (ii) ARE PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) OF THE ORDER, NAMELY HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED UPON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS DOCUMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

THE DISTRIBUTION OF THIS DOCUMENT IN OTHER JURISDICTIONS OR TO RESIDENTS OF OTHER JURISDICTIONS MAY ALSO BE RESTRICTED BY LAW, AND PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY SUCH RESTRICTIONS. BY ACCEPTING THIS REPORT YOU AGREE TO BE BOUND BY THE FOREGOING INSTRUCTIONS. YOU SHALL INDEMNIFY EQUINET BANK AGAINST ANY DAMAGES, CLAIMS, LOSSES, AND DETRIMENTS RESULTING FROM OR IN CONNECTION WITH THE UNAUTHORIZED USE OF THIS DOCUMENT.

This report is for informational purposes only and has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. This publication is intended to provide information to assist institutional investors in making their own investment decisions, not to provide investment advice to any specific investor. Therefore, investments discussed and recommendations made herein may not be suitable for all investors: readers must exercise their own independent judgment as to the suitability of such investments and recommendations in the light of their own investment objectives, experience, taxation status and financial position.

The information herein is believed by Equinet Bank to be reliable and has been obtained from sources believed to be reliable, but Equinet Bank makes no representation as to the accuracy or completeness of such information. The information given in this report is subject to change without notice; it may be incomplete or condensed and it may not contain all material information concerning the Company. Opinions expressed herein may differ or be contrary to opinions expressed by other business areas of the Equinet Bank group as a result of using different assumptions and criteria. Equinet Bank is under no obligation to update or keep the information current. Equinet Bank provides data concerning the future development of securities in the context of its usual research activity. However, if a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results. Neither the author nor Equinet Bank accepts any liability whatsoever for any loss howsoever arising from any use of this publication or its contents or otherwise arising in connection herewith, except as provided for under applicable regulations.

Equinet Bank shall only be liable for any damages intentionally caused or which result from any gross negligence of Equinet Bank. Further Equinet Bank shall be liable for the breach of a material obligation of Equinet Bank, however, limited to the amount of the typical foreseeable which shall in no event exceed the amount of EUR 10,000. German law shall be applicable and court of jurisdiction for all disputes shall be Frankfurt/Main (Germany).

### Competent Supervisory Authority:

Bundesanstalt für Finanzdienstleistungsaufsicht  
-BaFin- (Federal Financial Supervisory Authority)  
Graurheindorfer Straße 108, 53117 Bonn and  
Marie-Curie-Str. 24-28, 60439 Frankfurt am Main.



Recommendation history for EUROMICRON AG

Date	Recommendation	Target price	Price at change date
03. Apr 14	Buy	19.00	13.08
12. Nov 13	Buy	24.00	16.27
07. Sep 12	Buy	30.00	19.90
29. Mrz 12	Buy	31.50	22.16
15. Aug 11	Buy	30.26	18.36
27. Apr 11	Buy	28.82	19.94

Source: Factset & ESN, price data adjusted for stock splits.  
 This chart shows Equinet Bank continuing coverage of this stock; the current analyst may or may not have covered it over the entire period. Current analyst: Adrian Pehl, CFA (since 28/04/2010)





## ESN Recommendation System

The ESN Recommendation System is **Absolute**. It means that each stock is rated on the basis of a **total return**, measured by the upside potential (including dividends and capital reimbursement) over a **12 month time horizon**.


The ESN spectrum of recommendations (or ratings) for each stock comprises 5 categories: **Buy, Accumulate (or Add), Hold, Reduce and Sell (in short: B, A, H, R, S)**.

Furthermore, in specific cases and for a limited period of time, the analysts are allowed to rate the stocks as **Rating Suspended (RS)** or **Not Rated (NR)**, as explained below.

### Meaning of each recommendation or rating:

- **Buy:** the stock is expected to generate total return of **over 20%** during the next 12 months time horizon
- **Accumulate:** the stock is expected to generate total return of **10% to 20%** during the next 12 months time horizon
- **Hold:** the stock is expected to generate total return of **0% to 10%** during the next 12 months time horizon.
- **Reduce:** the stock is expected to generate total return of **0% to -10%** during the next 12 months time horizon
- **Sell:** the stock is expected to generate total return **under -10%** during the next 12 months time horizon
- **Rating Suspended:** the rating is suspended due to a capital operation (take-over bid, SPO, ...) where the issuer of the document (a partner of ESN) or a related party of the issuer is or could be involved or to a change of analyst covering the stock
- **Not Rated:** there is no rating for a company being floated (IPO) by the issuer of the document (a partner of ESN) or a related party of the issuer

### Equinet Bank Ratings Breakdown



### History of ESN Recommendation System

**Since 18 October 2004**, the Members of ESN are using an Absolute Recommendation System (before was a Relative Rec. System) to rate any single stock under coverage.

**Since 4 August 2008**, the ESN Rec. System has been amended as follow.

- Time horizon changed to 12 months (it was 6 months)
- Recommendations Total Return Range changed as below:

#### TODAY



#### BEFORE



## Disclaimer:

These reports have been prepared and issued by the Members of European Securities Network LLP ('ESN'). ESN, its Members and their affiliates (and any director, officer or employee thereof), are neither liable for the proper and complete transmission of these reports nor for any delay in their receipt. Any unauthorised use, disclosure, copying, distribution, or taking of any action in reliance on these reports is strictly prohibited. The views and expressions in the reports are expressions of opinion and are given in good faith, but are subject to change without notice. These reports may not be reproduced in whole or in part or passed to third parties without permission. The information herein was obtained from various sources. ESN, its Members and their affiliates (and any director, officer or employee thereof) do not guarantee their accuracy or completeness, and neither ESN, nor its Members, nor its Members' affiliates (nor any director, officer or employee thereof) shall be liable in respect of any errors or omissions or for any losses or consequential losses arising from such errors or omissions. Neither the information contained in these reports nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities or any options, futures or other derivatives related to such securities ('related investments'). These reports are prepared for the clients of the Members of ESN only. They do not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive any of these reports. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment strategies discussed or recommended in these reports and should understand that statements regarding future prospects may not be realised. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in these reports. In addition, investors in securities such as ADRs, whose value are influenced by the currency of the underlying security, effectively assume currency risk.

ESN, its Members and their affiliates may submit a pre-publication draft (without mentioning neither the recommendation nor the target price/fair value) of its reports for review to the Investor Relations Department of the issuer forming the subject of the report, solely for the purpose of correcting any inadvertent material inaccuracies. Like all members employees, analysts receive compensation that is impacted by overall firm profitability. For further details about the specific risks of the company and about the valuation methods used to determine the price targets included in this report/note, please refer to the latest relevant published research on single stock or contact the analyst named on the front of the report/note. Research is available through your sales representative. ESN will provide periodic updates on companies or sectors based on company-specific developments or announcements, market conditions or any other publicly available information. Unless agreed in writing with an ESN Member, this research is intended solely for internal use by the recipient. Neither this document nor any copy of it may be taken or transmitted into Australia, Canada or Japan or distributed, directly or indirectly, in Australia, Canada or Japan or to any resident thereof. This document is for distribution in the U.K. Only to persons who have professional experience in matters relating to investments and fall within article 19(5) of the financial services and markets act 2000 (financial promotion) order 2005 (the "order") or (ii) are persons falling within article 49(2)(a) to (d) of the order, namely high net worth companies, unincorporated associations etc (all such persons together being referred to as "relevant persons"). This document must not be acted on or relied upon by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons. The distribution of this document in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. By accepting this report you agree to be bound by the foregoing instructions. You shall indemnify ESN, its Members and their affiliates (and any director, officer or employee thereof) against any damages, claims, losses, and detriments resulting from or in connection with the unauthorized use of this document.

For disclosure upon "conflicts of interest" on the companies under coverage by all the ESN Members and on each "company recommendation history", please visit the ESN website ([www.esnpartnership.eu](http://www.esnpartnership.eu)). For additional information and individual disclaimer please refer to [www.esnpartnership.eu](http://www.esnpartnership.eu) and to each ESN Member websites:

[www.bancaakros.it](http://www.bancaakros.it) regulated by the CONSOB - Commissione Nazionale per le Società e la Borsa

[www.bekafinance.com](http://www.bekafinance.com) regulated by CNMV - Comisión Nacional del Mercado de Valores

[www.caixabi.pt](http://www.caixabi.pt) regulated by the CMVM - Comissão do Mercado de Valores Mobiliários

[www.cgdsecurities.com.br](http://www.cgdsecurities.com.br) regulated by the CVM - Comissão de Valores Mobiliários

[www.cmcics.com](http://www.cmcics.com) regulated by the AMF - Autorité des marchés financiers

[www.degroof.be](http://www.degroof.be) regulated by the FSMA - Financial Services and Markets Authority

[www.equinet-ag.de](http://www.equinet-ag.de) regulated by the BaFin - Bundesanstalt für Finanzdienstleistungsaufsicht

[www.ibg.gr](http://www.ibg.gr) regulated by the HCMC - Hellenic Capital Market Commission

[www.pohjola.com](http://www.pohjola.com) regulated by the Financial Supervision Authority

[www.snssecurities.nl](http://www.snssecurities.nl) regulated by the AFM - Autoriteit Financiële Markten

## Members of ESN (European Securities Network LLP)



**Banca Akros S.p.A.**  
Viale Eginardo, 29  
20149 MILANO  
Italy  
Phone: +39 02 43 444 389  
Fax: +39 02 43 444 302



**Equinet Bank AG**  
Gräbstraße 97  
60487 Frankfurt am Main  
Germany  
Phone: +49 69 - 58997 - 410  
Fax: +49 69 - 58997 - 299



**Bank Degroof**  
Rue de l'Industrie 44  
1040 Brussels  
Belgium  
Phone: +32 2 287 91 16  
Fax: +32 2 231 09 04



**Investment Bank of Greece**  
32 Aigialeias Str & Paradissou,  
151 25 Maroussi,  
Greece  
Tel: +30 210 81 73 383



**BEKA Finance**  
Serrano, 39  
28001 Madrid  
Spain  
Phone: +34 91 436 7813  
Fax: +34 91 577 3770



**Pohjola Bank plc**  
P.O.Box 308  
FI-00013 Pohjola  
Finland  
Phone: +358 10 252 011  
Fax: +358 10 252 2703



**Caixa-Banco de Investimento**  
Rua Barata Salgueiro, nº 33  
1269-057 Lisboa  
Portugal  
Phone: +351 21 313 73 00  
Fax: +351 21 389 68 98



**SNS Securities N.V.**  
Nieuwezijds Voorburgwal 162  
P.O.Box 235  
1000 AE Amsterdam  
The Netherlands  
Phone: +31 20 550 8500  
Fax: +31 20 626 8064



**CM - CIC Securities**  
6, avenue de Provence  
75441 Paris  
Cedex 09  
France  
Phone: +33 1 4596 7940  
Fax: +33 1 4596 7748

